Balanced news tone
News Sentiment
COAG sentiment intelligence
Hemab Therapeutics Holdings, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
81/100 classification confidence.
directly relevant articles
high-authority source matches
+22.7% over one week, +52.2% over four weeks, trend inactive, and materially above fair value.
Hemab Therapeutics (NASDAQ:COAG) Trading Down 3.8% - Should You Sell?
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Hemab Therapeutics IPO Debut Puts COAG And Pipeline Risks In Focus
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 03 May 2026 07:00
- Source
- Market source
Hemab Therapeutics Holdings Company Profile & Introduction
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 May 2026 07:00
- Source
- Moomoo
COAG|Hemab Therapeutics Holdings Ord Shs (Proposed)|Price:38.030|Chg%:+0.830
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 May 2026 07:00
- Source
- TradingKey
Hemab prices $301M in latest upsized biopharma IPO
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 May 2026 07:00
- Source
- BioWorld News
HEMAB THERAPEUTICS HOLDINGS (COAG) Stock Price, News & Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Apr 2026 23:25
- Source
- Stock Titan
$301.5M biotech IPO puts Hemab on Nasdaq as COAG Friday
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Apr 2026 07:00
- Source
- Stock Titan
Bleeding disorder firm Hemab upsizes proposed IPO to 15M shares
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Apr 2026 07:00
- Source
- Seeking Alpha
GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Apr 2026 07:00
- Source
- StockStory
Seaport, Hemab launch US IPOs as biotech listings gather momentum
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Apr 2026 07:00
- Source
- Reuters
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 22 Apr 2026 07:00
- Source
- Seeking Alpha
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
COAG Stock Price and Chart — NASDAQ:COAG
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Apr 2026 13:09
- Source
- TradingView
Long waiting lists and geopolitical headwinds could pose a challenge to Hemab’s IPO plans
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Apr 2026 07:00
- Source
- medwatch.com
Hemab Therapeutics moving towards Nasdaq IPO
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Apr 2026 07:00
- Source
- AllSci
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 18 Mar 2026 07:00
- Source
- Market source
Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Feb 2026 09:53
- Source
- Kavout | AI
Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook
- Tone
- Positive 82/100
- Event
- Earnings
- Published
- 26 Feb 2026 08:00
- Source
- TIKR.com
Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 25 Feb 2026 08:00
- Source
- TIKR.com
This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Feb 2026 08:00
- Source
- Barron's
UnitedHealth Stock Plummets 20% After Earnings. Why Soft Revenue Isn’t the Only Problem.
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 Jan 2026 08:00
- Source
- Barron's